Fig. 5.

Eps8-specific, HLA-A2.1-restricted lysis of diverse tumor cell types by in vivo peptide-primed specific T cells. Peptide-primed specific T cells from immunized mice were assessed for their cytotoxicity against a MCF-7 cells with (HLA-A2.1⁺, Eps8⁺) or without anti-HLA-A2 antibody (HLA-A2.1⁻, Eps8⁺), and Eps8-attenuated MCF-7 cells (HLA-A2.1⁺, Eps8⁻), at a 50:1 E/T ratio. Other HLA-A2.1- and Eps8-expressing cancer cells b HCT-116, c U251, and d SW480 cells were also assessed at different E/T ratios. Experiments were performed in triplicate. Data are represented as the mean ± S.D